Ophthalmic manifestations of systemic disease: Viva

This is a branching oral built to probe the reasoning that holds the silent uveitis and the screening schedule at the centre, and to expose the candidate who has memorised the headline without the safety-critical corners. The questions escalate from the framing of the ophthalmic risk to the screening schedule, the stepwise treatment, and the contrast with the diabetes, the neurofibromatosis and the metabolic eye signs, with deliberate probes into the red flags and the global child health. [1]

Opening question: framing the ophthalmic risk

The examiner opens with the swollen knee and the positive antinuclear antibody and asks: what is the ophthalmic risk in this child, and what is your first step? [1]

A strong answer names the chronic anterior uveitis of the juvenile idiopathic arthritis as the sight-threatening silent inflammation, and states that the first step is the slit-lamp screening by the ophthalmology service at the high-risk interval. [1]

Model answer. This child carries the highest risk of the chronic anterior uveitis of any child in the clinic, because the oligoarticular antinuclear-antibody-positive disease in the young child is the profile that carries the uveitis in the greatest proportion, yet the uveitis is silent and produces no eye symptom. The first step is the slit-lamp screening by the ophthalmology service at the every-three-months interval, because the slit-lamp is the only detection of the cells and the flare before they scar the anterior chamber. [1]

Probe one: the screening schedule

The examiner presses: what is the screening schedule, and how does it change as the risk falls? [1]

A strong answer recites the ACR schedule and the risk factors. The high-risk child with the oligoarticular or the polyarticular rheumatoid-factor-negative disease, the positive antinuclear antibody, the onset under seven years and the duration under four years receives the slit-lamp every three months. As the factors fall away, the interval lengthens to every six months and then every twelve months, and the screening continues for years after the arthritis remits. [1]

Pitfall probe. Why does the screening continue after the arthritis remits? Because the uveitis may flare in the quiet joint, and the silent inflammation may scar the eye even when the joint is settled, so the screening never stops while the risk remains. [1]

Probe two: the stepwise treatment

The examiner asks: how do you treat the chronic uveitis stepwise? [1]

A strong answer builds the ladder the boards reward. The topical corticosteroid, the prednisolone acetate one percent, is the first line for the acute inflammation, and the cycloplegic prevents the posterior synechiae. The methotrexate, at ten to fifteen milligrams per square metre once weekly, is the first-line steroid-sparing systemic agent when the topical steroid fails or the steroid toxicity threatens the sight. The adalimumab, the anti-tumour-necrosis-factor monoclonal antibody, is the standard second-line biologic when the methotrexate fails. [1]

Pitfall probe. What are the complications of the untreated uveitis? The band keratopathy, the cataract, the posterior synechiae, the secondary glaucoma and the amblyopia of the deprivation, and these are the reasons the screening and the early treatment transform the prognosis. [1]

Branch one: the type one diabetes

The examiner pivots: imagine instead a teenager with the type one diabetes. What is the ocular screening, and why does the interval differ? [2]

A strong answer names the diabetic retinopathy and the annual screening from age eleven after two to five years of the disease. The retinopathy is the microvascular complication of the chronic hyperglycaemia, it is rare before five years of duration but rises steeply through the teenage years, and the annual dilated fundus examination or the retinal photography is the screening. The tight glycaemic and blood-pressure control prevents the progression, and the laser treats the proliferative disease. The annual interval contrasts with the three-monthly interval of the juvenile arthritis, because the retinopathy is slower and declared by the duration. [2]

Pitfall probe. Why does the sickle retinopathy screen from age ten and not at the diabetes interval? The proliferative sickle retinopathy is the vasculopathy of the sickle haemoglobin, it begins in the retinal periphery in the adolescence, and the annual dilated fundus from age ten with the laser for the high-risk sea-fan neovascularisation is the standard. [7]

Branch two: the neurofibromatosis optic pathway glioma

The examiner pivots again: imagine a child with the neurofibromatosis type one who develops the reduced vision. What is this, and what is the screening? [4]

A strong answer names the optic pathway glioma, the low-grade pilocytic astrocytoma of the optic nerve, the chiasm and the hypothalamus, which develops in roughly fifteen percent of the children and is the commonest central nervous system tumour of the disease. The annual ophthalmology review with the visual acuity, the colour vision and the fundus is performed through the childhood, with the surveillance magnetic resonance imaging in the first years, because the glioma may grow silently before it compresses the visual pathway. The reduced vision, the proptosis or the precocious puberty is the red flag that demands the urgent imaging. [4]

Pitfall probe. What other ocular signs does the neurofibromatosis carry? The Lisch nodules of the iris, the cafe-au-lait patches and the axillary freckling, and the sphenoid wing dysplasia, and the candidate who links the sign to the disease demonstrates the breadth. [4]

Branch three: the metabolic eye signs

The examiner pivots again: name two metabolic or connective tissue eye signs and the underlying disease. [9]

A strong answer names the Kayser-Fleischer ring of the Wilson disease, the brown-green copper deposit in the Descemet membrane at the limbus, and the ectopia lentis of the Marfan syndrome, the superotemporal dislocation of the lens from the fibrillin defect. The cherry-red spot of the Tay-Sachs and the Niemann-Pick, the corneal clouding of the mucopolysaccharidoses, and the night blindness and the Bitot spots of the vitamin A deficiency complete the metabolic picture. [9][8]

Pitfall probe. What is the direction of the lens dislocation in the Marfan and the homocystinuria? The Marfan dislocates the lens superotemporally, the upward and the outward, while the homocystinuria dislocates the lens inferonasally, the downward and the inward, and the direction is the high-yield discriminator the boards reward. [9]

Closing question: the global child health

The examiner closes: what is the leading cause of the preventable childhood blindness across the world, and how is it managed? [8]

A strong answer names the vitamin A deficiency and the xerophthalmia. The night blindness is the earliest sign, the Bitot spot is the conjunctival sign, and the keratomalacia is the corneal melting that blinds within the days, and the high-dose vitamin A supplementation in the regions of the malnutrition, the malabsorption and the measles reduces the mortality and the blindness. The candidate who links the ocular manifestation to the global equity demonstrates the reasoning the boards reward. [8]